Vimarsana
Biggest News Aggregation in the World

Page 4 - Genetics Service News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Service Today - Breaking & Trending Today

Phase II of Singapore's National Precision Medicine strategy to begin in April 2021 - Vimarsana News

Phase II of Singapore's National Precision Medicine strategy to begin in April 2021

Phase II of Singapore's National Precision Medicine strategy to begin in April 2021 Precision medicine is part of Singapore's Research, Innovation and Enterprise (RIE) 2025 strategic goal to transform and protect the health of every Singaporean. Identified as a priority by the Ministry of Health, precision medicine aims to understand how genomic, phenotypic, lifestyle and clinical factors contribute to the health of Singaporeans. It also supports the responsible use of health data in clinical applications with the longer-term goal of addressing Singapore's healthcare challenges in a sustainab...

Singapore launches next phase of National Precision Medicine Programme - Vimarsana News

Singapore launches next phase of National Precision Medicine Programme

Singapore launches next phase of National Precision Medicine Programme New national body established to further research insights, improve patient outcomes and create new economic opportunities for the biomedical technology industry. Precision Health Research, Singapore SINGAPORE, 7 April 2021 – Precision medicine is part of Singapore’s Research, Innovation and Enterprise (RIE) 2025 strategic goal to transform and protect the health of every Singaporean. Identified as a priority by the Ministry of Health, precision medicine aims to understand how genomic, phenotypic, lifestyle and clini...

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021 - Vimarsana News

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021

Share this article Share this article ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, will be presented at the 17 th Annual WORLD Symposium™. "We are pleased to report additional positive data from Cohorts 1 and 2 of our ongoing Phase I/II trial of RGX-121. Data from the eight patients d...

Over one in three rare childhood disorders diagnosed in six years - Vimarsana News

Over one in three rare childhood disorders diagnosed in six years

• Sets pace for targeted therapy development among those diagnosed 22 December 2020, Singapore – For over 20 years, the Genetics Service at the KK Women’s and Children’s Hospital (KKH) has been providing clinical care to patients with genetic disorders. In 2014, BRIDGES (Bringing Research Innovations for the Diagnosis of GEnetic diseases in Singapore) was set up, in collaboration with genomic research institutes at SingHealth, Agency for Science, Technology and Research (A*STAR) and Duke-NUS to synergise the diagnostic efforts and patient outcome management. After six years, t...

Over one in 3 rare childhood disorders diagnosed in 6 years - Vimarsana News

Over one in 3 rare childhood disorders diagnosed in 6 years

Credit: A*STAR's Genome Institute of Singapore (GIS) 22 December 2020, Singapore - For over 20 years, the Genetics Service at the KK Women's and Children's Hospital (KKH) has been providing clinical care to patients with genetic disorders. In 2014, BRIDGES (Bringing Research Innovations for the Diagnosis of GEnetic diseases in Singapore) was set up, in collaboration with genomic research institutes at SingHealth, Agency for Science, Technology and Research (A*STAR) and Duke-NUS to synergise the diagnostic efforts and patient outcome management. After six years, the KKH has met the goals set o...